Traws Pharma grants 97,000 stock options to CSO

Traws Pharma, Inc. reported a compensation-related insider transaction for Chief Science Officer Virology Charles David Pauza.

Accepted by SEC EDGAR 07/16/2026 - 12:39 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Traws Pharma, Inc. reported a compensation-related insider transaction for Chief Science Officer Virology Charles David Pauza. He received a grant of 97,000 stock options on July 9, 2026, with an exercise price of $0.68 per share, vesting 100% on July 9, 2027 and expiring July 9, 2036. Following the award, he directly holds options for 97,000 underlying shares of common stock.

Insider Trade Summary

Grant/Award: 97,000 shares

Grant/Award 1 txn

Insider Pauza Charles David

Role Chief Science Officer Virology

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy) F1	97,000	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 97,000 contracts (Direct)

Holdings Before and After: Stock Option (right to buy), 0 to 97,000 contracts (Direct)

Footnotes (1)

1. F1. Represents stock options awarded by the Issuer's compensation committee (comprised of independent directors) to the reporting person under the Issuer's 2021 Incentive Compensation Plan, as amended and/or restated through the date hereof. The stock options under this award will vest 100% on the first anniversary of the grant date.

Key Figures

Stock options granted: 97,000 shares Exercise price: $0.6800 per share Vesting date: July 9, 2027 +2 more

5 metrics

Stock options granted 97,000 shares Stock Option grant to Charles David Pauza on July 9, 2026

Exercise price $0.6800 per share Exercise price for the 97,000 stock options

Vesting date July 9, 2027 Options vest 100% on the first anniversary of the grant date

Expiration date July 9, 2036 Expiration of Pauza’s stock option award

Derivative securities held after grant 97,000 options Total stock options held directly following the reported award

Key Terms

Stock Option (right to buy), exercise price, 2021 Incentive Compensation Plan, vesting 100% on the first anniversary

4 terms

Stock Option (right to buy) financial

"security_title is reported as Stock Option (right to buy)"

exercise price financial

"conversion_or_exercise_price is disclosed as an exercise price of $0.6800"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

2021 Incentive Compensation Plan financial

"awarded under the Issuer's 2021 Incentive Compensation Plan, as amended"

vesting 100% on the first anniversary financial

"The stock options under this award will vest 100% on the first anniversary"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Traws Pharma (TRAW) report for Charles David Pauza?

Traws Pharma reported that Chief Science Officer Virology Charles David Pauza received a grant of 97,000 stock options on July 9, 2026. These options are a compensation award and give him the right to buy common stock at a fixed exercise price.

How many Traws Pharma (TRAW) stock options were granted to Pauza and at what exercise price?

Pauza was granted 97,000 stock options with an exercise price of $0.68 per share. Each option represents the right to buy one share of Traws Pharma common stock at that price once the options have vested.

When do Charles David Pauza’s Traws Pharma (TRAW) stock options vest?

The stock options granted to Pauza will vest 100% on July 9, 2027, the first anniversary of the July 9, 2026 grant date. Vesting means he can then exercise the options to purchase common shares at the agreed exercise price.

What is the expiration date of Pauza’s Traws Pharma (TRAW) stock options?

Pauza’s stock option award is scheduled to expire on July 9, 2036. After this expiration date he would no longer be able to exercise any unexercised options from this grant, even if they have vested by that time.

Under which plan were Pauza’s Traws Pharma (TRAW) options granted?

The options were granted under Traws Pharma’s 2021 Incentive Compensation Plan, as amended and/or restated. The filing notes the award was approved by the company’s compensation committee, which is comprised of independent directors overseeing executive equity compensation.

What is Charles David Pauza’s position at Traws Pharma (TRAW) according to this filing?

According to the filing, Charles David Pauza serves as Chief Science Officer Virology at Traws Pharma. The reported transaction reflects an equity compensation award tied to his role, aligning part of his potential future compensation with the company’s share performance.

How many derivative securities does Pauza hold after this Traws Pharma (TRAW) option grant?

After the grant, Pauza directly holds 97,000 stock options relating to Traws Pharma common stock. These options all come from this single July 9, 2026 award and together represent rights to purchase 97,000 underlying common shares once vested and before expiration.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Pauza Charles David

(Last) (First) (Middle)

C/O TRAWS PHARMA, INC.

12 PENNS TRAIL

(Street)

NEWTOWN PENNSYLVANIA 18940

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Traws Pharma, Inc. [ TRAW ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Science Officer Virology

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$0.68	07/09/2026		A		97,000		07/09/2027(1)	07/09/2036	Common Stock	97,000	$0	97,000	D

Explanation of Responses:

1. Represents stock options awarded by the Issuer's compensation committee (comprised of independent directors) to the reporting person under the Issuer's 2021 Incentive Compensation Plan, as amended and/or restated through the date hereof. The stock options under this award will vest 100% on the first anniversary of the grant date.

	/s/ Charles D. Pauza	07/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)